Read the full press release here.
The incredible academic work from The University of Pennsylvania is moving to biotech, where patients can be directly impacted. No one better to lead this effort than Dr. Jim Wilson.
The investigational gene therapy program for Angelman syndrome, known as GTP-220, is still owned by FAST and being run in collaboration with Dr. Wilson’s scientific team exactly as before. The change from an academic environment to a corporate entity will not impact the program deliverables or timelines. The money invested in the AS program is 100% being spent only on the GTP-220 program per the objectives of the sponsored research agreement, like every program we fund. Everyone is held to milestones and deliverables. FAST is continuing to closely control that program through IND and this news has no negative impact on the gene therapy program for Angelman syndrome. We expect this development will only improve efficiencies. This is good for all programs that were at UPenn, including AS.
More updates about investigational GTP-220 at the FAST Science Summit – registration is now open.